^
Association details:
| Biomarker: | TTF1 expression + NAPSA expression + PD-L1 expression + TMB-H |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Neoadjuvant Programmed Cell Death Protein 1 Blockade Combined With Stereotactic Body Radiation Therapy for Stage III(N2) Non-Small Cell Lung Cancer: A Case Series
Published date:
03/07/2022
Excerpt:
In June 2020, a 68-year-old man with complaints of cough and expectoration of bloody sputum was admitted to Jinling Hospital….Histologic analysis of CT-guided percutaneous lung puncture biopsies of the primary lesion showed poorly differentiated adenocarcinoma in the lung...Immunohistochemistry (IHC) showed TTF1 (3+) expression, NapsinA (1+)-positive (weak) staining...IHC showed PD-1 ligand 1 (PD-L1) expression in 80% of the cancer cells...Next-generation sequencing (NGS) did not reveal any TKI-targetable mutations and high TMB (18.46 Muts/Mb)....Computed tomographic (CT) scans after two cycles of toripalimab showed tumor partial response(PR), with a significant decrease in the left lung mass...
DOI:
https://doi.org/10.3389/fonc.2022.779251
